2OOS

Crystal structure of plasmodium falciparum enoyl ACP reductase with triclosan reductase


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.10 Å
  • R-Value Free: 0.227 
  • R-Value Work: 0.192 
  • R-Value Observed: 0.194 

Starting Model: experimental
View more details

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.3 of the entry. See complete history


Literature

X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalarial efficacy

Freundlich, J.S.Wang, F.Tsai, H.-C.Kuo, M.Shieh, H.-M.Anderson, J.W.Nkrumah, L.J.Valderramos, J.-C.Yu, M.Kumar, T.R.S.Valderramos, S.G.Jacobs, W.R.Schiehser, G.A.Jacobus, D.P.Fidock, D.A.Sacchettini, J.C.

(2007) J Biol Chem 282: 25436-25444

  • DOI: https://doi.org/10.1074/jbc.M701813200
  • Primary Citation of Related Structures:  
    2FOI, 2NQ8, 2OL4, 2OOS, 2OP0, 2OP1

  • PubMed Abstract: 

    The x-ray crystal structures of five triclosan analogs, in addition to that of the isoniazid-NAD adduct, are described in relation to their integral role in the design of potent inhibitors of the malarial enzyme Plasmodium falciparum enoyl acyl carrier protein reductase (PfENR). Many of the novel 5-substituted analogs exhibit low micromolar potency against in vitro cultures of drug-resistant and drug-sensitive strains of the P. falciparum parasite and inhibit purified PfENR enzyme with IC50 values of <200 nM. This study has significantly expanded the knowledge base with regard to the structure-activity relationship of triclosan while affording gains against cultured parasites and purified PfENR enzyme. In contrast to a recent report in the literature, these results demonstrate the ability to improve the in vitro potency of triclosan significantly by replacing the suboptimal 5-chloro group with larger hydrophobic moieties. The biological and x-ray crystallographic data thus demonstrate the flexibility of the active site and point to future rounds of optimization to improve compound potency against purified enzyme and intracellular Plasmodium parasites.


  • Organizational Affiliation

    Department of Medicinal Chemistry, Jacobus Pharmaceutical Company, Princeton, New Jersey 08540, USA. joelf@princeton.edu


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Enoyl-acyl carrier reductase
A, B
338Plasmodium falciparumMutation(s): 0 
Gene Names: FabI
EC: 1.3.1.9
UniProt
Find proteins for Q9BJJ9 (Plasmodium falciparum)
Explore Q9BJJ9 
Go to UniProtKB:  Q9BJJ9
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ9BJJ9
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Binding Affinity Annotations 
IDSourceBinding Affinity
JPJ BindingDB:  2OOS IC50: 76 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.10 Å
  • R-Value Free: 0.227 
  • R-Value Work: 0.192 
  • R-Value Observed: 0.194 
  • Space Group: P 43 21 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 131.221α = 90
b = 131.221β = 90
c = 83.163γ = 90
Software Package:
Software NamePurpose
REFMACrefinement
CrystalCleardata collection
HKL-2000data reduction
HKL-2000data scaling
XFITdata reduction

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

Deposition Data

  • Released Date: 2007-07-17 
  • Deposition Author(s): Tsai, H.

Revision History  (Full details and data files)

  • Version 1.0: 2007-07-17
    Type: Initial release
  • Version 1.1: 2008-05-01
    Changes: Version format compliance
  • Version 1.2: 2011-07-13
    Changes: Derived calculations, Version format compliance
  • Version 1.3: 2023-08-30
    Changes: Data collection, Database references, Derived calculations, Refinement description